Somewhat surprisingly, the ribonuclease catalytic activity of RNASET2 may not be required for its oncosuppressive activity or stress mediated cell death ( (5, 20) The efficacy of human recombinant RNASET2 in inhibiting tumor growth, cytoskeletal reorganization and inflammatory response in several disease models supports the potential for RNASET2 as a soluble therapeutic drug (6, 18, 21, 22). This evidence concerns the gene RNASET2 and neoplasm.